Skip to main content
BIIB
NASDAQ Life Sciences

Q4 Revenue Beat for Biogen as $2B Drug Candidate Enters Phase III Trials

Tom Rudovsky · Reported by Wiseek News
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$188.41
Mkt Cap
$27.651B
52W Low
$110.035
52W High
$202.41
52W Position info
71% above low
Off High info
6.9% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

BIIB sits 71% above its 52-week low of $110.035.

Summary

Biogen reported Q4 revenues of $2.28 billion, surpassing forecasts by 3.6% and exceeding EPS guidance, indicating stronger-than-expected operational performance. Concurrently, its drug candidate Felzartamab has advanced into Phase III trials for kidney and autoimmune diseases, representing a significant pipeline catalyst with a U.S. market potential exceeding $2 billion. This positive Q4 performance and material pipeline progression offer a more optimistic near-term outlook, contrasting with the 'significant decline in diluted EPS' noted in the company's 2025 annual report filed in February. The advancement of Felzartamab could unlock a substantial new revenue stream, materially impacting Biogen's long-term growth trajectory. Traders will closely monitor the clinical trial results for Felzartamab and subsequent earnings reports for sustained momentum.

At the time of this announcement, BIIB was trading at $188.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $27.7B. The 52-week trading range was $110.04 to $202.41. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.


Price Chart

Share this article

Copied!

BIIB - Latest Insights

BIIB
Nov 18, 2026, 11:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $249.28
Real-time Price: $247.82 info
Change: -$1.46 (-0.59%) info
Market Cap: $36.531B info
BIIB
Nov 17, 2026, 4:45 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $253.00
Real-time Price: $247.82 info
Change: -$5.18 (-2%) info
Market Cap: $36.531B info
BIIB
Nov 09, 2026, 1:02 AM EST
Source: Reuters
Importance Score:
8
Price at Filing: $248.35
Real-time Price: $247.82 info
Change: -$0.530 (-0.21%) info
Market Cap: $36.531B info
BIIB
Oct 28, 2026, 6:23 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $252.73
Real-time Price: $247.82 info
Change: -$4.91 (-2%) info
Market Cap: $36.531B info
BIIB
Oct 28, 2026, 6:07 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $252.73
Real-time Price: $247.82 info
Change: -$4.91 (-2%) info
Market Cap: $36.531B info